candesartan has been researched along with daunorubicin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Aizawa, Y; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, S; Prakash, P; Soga, M; Tachikawa, H; Veeraveedu, P; Watanabe, K | 1 |
1 review(s) available for candesartan and daunorubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for candesartan and daunorubicin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; Calcium-Transporting ATPases; Cardiomyopathies; Cytoprotection; Daunorubicin; Disease Models, Animal; Electrocardiography; Fas Ligand Protein; Male; Membrane Glycoproteins; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Survival Rate; Tetrazoles; Tumor Necrosis Factors | 2006 |